Full Text View
Tabular View
No Study Results Posted
Related Studies
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response (AFR22)
This study has been terminated.
Study NCT00210119   Information provided by Institut Bergonié

First Received on September 12, 2005.   Last Updated on December 29, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myeloid Leukemia, Chronic
Additional conditions recognized in this trial
Chronic Disease
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
More general conditions related to this trial
Bone Marrow Diseases
Disease Attributes
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Additional drug interventions recognized in this trial
Diphosphonates
Imatinib
Zoledronic acid
More general drug interventions related to this trial
Antineoplastic Agents
Bone Density Conservation Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Institut Bergonié
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services